secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002688
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027
--------------------------------------------------------------------------------

- Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.
- Phase 2 TibuSURE trial in SSc: topline data anticipated in first half of 2027.
- Cash and equivalents sufficient to fund operations through 2027, beyond both data readouts.
- Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/0001104659-26-002688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/tm262894d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer